Compare · HEPA vs NVO
HEPA vs NVO
Side-by-side comparison of Hepion Pharmaceuticals Inc. (HEPA) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HEPA and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 3025.1x HEPA ($71.2M).
- Over the past year, HEPA is up 0.0% and NVO is down 15.1% - HEPA leads by 15.1 points.
- HEPA has been more active in the news (20 items in the past 4 weeks vs 9 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 1 for HEPA).
- Company
- Hepion Pharmaceuticals Inc.
- Novo Nordisk A/S
- Price
- $0.32-17.57%
- $46.98-3.42%
- Market cap
- $71.2M
- $215.46B
- 1M return
- +0.00%
- -7.78%
- 1Y return
- +0.00%
- -15.08%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 20
- 9
- Recent ratings
- 1
- 25
Hepion Pharmaceuticals Inc.
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest HEPA
- SEC Form 4 filed by Interim CEO Stetz Gary S.
- SEC Form 4 filed by Executive Chairman Lopriore Vincent S
- SEC Form 4 filed by VP, Corp. Dev. Lopriore Chase
- SEC Form 4 filed by Director Fisher Danina
- SEC Form 4 filed by Director Liddy James Gordon
- SEC Form 4 filed by Chief Operating Officer Appajosyula Sireesh
- SEC Form 4 filed by Director Stetz Gary S. Ii
- SEC Form 3 filed by new insider Liddy James Gordon
- Hepion Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update
- SEC Form SCHEDULE 13D filed by Hepion Pharmaceuticals Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S